Interview With Peter Knauer, VP CMC: QbDVision Brings Digital CMC to Xeris Biopharma

Want a power-user look at QbDVision? Meet Peter Knauer, VP CMC at Xeris Biopharma.

An industry veteran and long-time advisor to our team, Peter has been using QbDVision since its earliest versions. Today, he leads the CMC function at Xeris Biopharma: a fast-growing organization that has already developed and commercialized multiple advanced products across a range of therapeutic areas.

As part of an ongoing transformation program, he and his team have put QbDVision at the heart of their evolving products and processes. Just recently, he was kind enough to sit down with us to offer some first-hand experiences with our platform – and to share how it’s helped Xeris streamline multiple key CMC workflows.

The following interview has been edited for content and clarity.

Tell us about your role at Xeris Biopharma.

Peter: I head up the CMC group at Xeris, which means I lead the team that quarterbacks the development of all our products. We’re responsible for all of the regulatory submissions at Xeris from preclinical filings to commercial submissions to post-commercial changes in our product lines.

Basically, if it’s related to “eCTD module 3” processes or inputs, it’s my and my team’s responsibility.

What are some of the challenges that motivated Xeris to adopt QbDVision?

Like just about any biopharma company, Xeris has a lot of different departments, internal stakeholders, and external resources that contribute to the overall drug product development and commercialization effort. And in the past, that has led to many familiar knowledge and data management challenges: lots of scattered documents, reports, and datasets, knowledge trapped in functional silos, and lots of time spent retrieving and consolidating the information we needed to create our deliverables. 

QbDVision gave Xeris one centralized repository for our data, documents, risk assessments, and more – everything that needs to flow through the CMC function. Today, it’s pretty much the only place we have to go when we need to pull canonical information into submissions that ultimately go to the FDA or other authorities. 

We do still maintain some special-purpose resources outside QbDVision – for example, lab archives and statistical packages for data generation. But QbDVision is now the ultimate repository for all official information that goes into a submission.

What were some of the biggest overall benefits of implementing QbDVIsion?

Before QbDVision, like a lot of biopharma companies, we worked mostly in Excel and Dropbox. We didn’t have core repositories for data, documents, or other information that wasn’t in our spreadsheets. We had a loose collective of files on SharePoint.

So when we needed to start a new project, the best we could do was copy one SharePoint file to another and then try to rework everything manually – changing names, changing risk assessments, and so on. All manually. It was slow and painful, especially when that approach was multiplied across different clinical programs and commercial products.

QbDVision gave Xeris one centralized repository for our data, documents, risk assessments, and more – everything that needs to flow through the CMC function.

Now, with everything centralized in QbDVision, one of the biggest benefits we’ve experienced is that we can take an earlier version of a project and clone it. For example, if we performed a risk assessment for an IND in QbDVision,  updating it is as simple as ctrl-D: use QbDVision’s cloning function to create a new version, update it, and you’re done. And you have an instant audit trail.

The shift from clinical to commercial processes is still a quantum leap, of course. But even there, QbDVIsion’s cloning capability enables us to demonstrate exactly how our processes and controls have evolved. If I need to, I can show the FDA risk assessment one, risk assessment two, risk assessment three, and so on. 

It’s an incredibly useful piece of software. And a huge time-saver.

Xeris is currently converting the delivery method of one of their products. How has QbDVision helped you with that process?

QbDVision’s cloning function has been a big advantage in this process too. It gives our users the ability to easily reuse and repurpose data from previous projects, instead of recreating it from scratch – which is what we’d typically need to do with legacy pen-and-paper methods. 

In the past, with all of our process knowledge stored in different places and formats, we had to reinvent a lot of wheels to switch product presentations. Core process flow, core materials, specifications, and parameters – we had to gather all that information from our current program and then manually rebuild it for a much more involved and complex delivery system.

Now, all of that core process information is prebuilt in QbDVision – how we compound it, filter it, fill it, package it, all ready to go. We can simply clone it forward for the new delivery format. We’re in the process of doing so for one of our active clinical programs, and it’s remarkable how much easier it is to build on work we’ve done before, instead of redoing it. It’s made this step much more seamless.

How has centralizing your data in QbDVision helped streamline post-approval change management at Xeris?

Any time the FDA grants approval for an NDA or BLA, they require drug developers to take a risk-based approach to any post-approval changes. QbDVision can help make that process a lot more efficient.

So for low-risk changes, a company may only need to report them in annual updates to the FDA, while medium risks can be reported via a change being effective (CBE) notification. In both the cases, there’s a good chance the FDA may not feel like it needs to give your data a close inspection. But with high-risk changes, they typically require a much more rigorous prior approval supplement (PAS) – and they will absolutely need to approve your data before you implement that change. 

That’s another area where QbDVision is tremendously useful. It makes it much easier for us to verify – and even more importantly, document – that we followed the proper risk assessment process to justify a change. Simply by following the risk management process in QbDVision, we’re fully prepared any time the FDA wants to assert any scrutiny on our processes, materials, or controls.

QbDVision gives us direct visibility into the steps, attributes, and parameters that may be affected, and helps us identify exactly where and why risk levels may be elevated by a post-approval change.

That’s especially valuable with major changes that can have a cascading impact, like changes in your raw materials or suppliers. QbDVision gives us direct visibility into the steps, attributes, and parameters that may be affected, and helps us identify exactly where and why risk levels may be elevated by a post-approval change. 

Today, QbDVision plays a particularly important role in helping us analyze and define risk levels related to our suppliers – especially those that supply excipients, API, and other relatively high-risk resources. QbDVision’s risk analysis features give us a really powerful way to pinpoint the level of risk associated with changing those resources, and then start a decision-making chain that’s ready for the FDA.

Which QbDVision features have been most valuable for Xeris’ tech transfer processes?

So I can tell some painful stories about the challenges we went through with Xeris’ first approved product: so many spreadsheets, loose and lost documents, SharePoint files, version control problems. 

It was a herculean effort to finalize our FDA submissions and initiate commercial production, largely because we pushed so much work to the very final stages of compilation and submission. We didn’t have a system in place to tell us what needed to be done by when, and why. 

QbDVision has a couple of key features that really helped us turn that situation around. 

By my estimate, using QbDVision helps shave anywhere from 6 to 12 months off our tech transfer timelines.

One is the “recommended actions” function, which for us is probably one of the most important datasets in the entire platform. It enables us to be very specific about when important steps need to be taken and why: for example, qualifying a material before a registration batch, so the CMAs for that material can be identified and leveraged in all the following steps. By following those recommended actions over time, we’re able to both de-risk our processes and demonstrate to the FDA how we did so. 

Another really, really important aspect of any tech transfer is the process flow, which QbDVision displays very effectively. Unit operations, process components and inputs, key material attributes, intermediate and final quality attributes – all of those things are beautifully visualized for both our internal team and the CDMOs who receive those process flows from us. It makes it very easy for everyone to understand both the overall structure of the process, the individual steps, and the context for each one.

Features like these have been extremely valuable in helping us get and keep CMC off the critical path for more recent products and development programs. By my estimate, using QbDVision helps shave anywhere from 6 to 12 months off our tech transfer timelines.

Any final thoughts on how QbDVision has helped Xeris enhance its CMC program?

So at every company I’ve worked for the last 30 years, the critical path has always run through either clinical or CMC – and a lot of the time it’s CMC. Clinical can’t start a study program until they get the materials manufactured and released, or commercial can’t ramp up because processes haven’t been transferred and validated on time. I’ve seen so many development cycles that run in fits and starts, with key workflows constantly piling up behind delayed CMC milestones.

QbDVision helps solve that. It allows us to progress in a more orderly way, and keep our CMC program in a more steady state of progress. We’re able to move the needle on a lot of work that we might otherwise have paused while we wait for inputs from other groups. We can get ahead of things much more adeptly.

And that is actually an astounding change to the way we do things.


Want to see results like these in your CMC program?

Reach out to our team at any time. We’d love to learn more about your team and pipeline, and explore how QbDVision can help you reach your operational goals.

Robert Dimitri, M.S., M.B.A.

Director Digital Quality Systems, Thermo Fisher Scientific

Robert Dimitri is a Director of Digital Quality Systems in Thermofisher’s Pharma Services Group. Previously he was a Digital Transformation and Innovation Lead in Takeda’s Business Excellence for the Biologics Operating Unit while leading Digital and Data Sciences groups in Manufacturing Sciences at Takeda’s Massachusetts Biologics Site.

Devendra Deshmukh

Global Head, Digital Science Business Operations, Thermo Fisher Scientific

Devendra Deshmukh currently leads Global Business Operations for Digital Science Solutions at Thermo Fisher Scientific. In this role he oversees operations broadly for the business across its product portfolio and leads the global professional services, technical support, and product education teams.

Grant Henderson

Sr. Dir. Manufacturing Science and Technology, VernalBio

Grant Henderson is the Senior Director of Manufacturing Science and Technology at Vernal Biosciences. He has years of expertise in pharmaceutical manufacturing process development/characterization, advanced design of experiments, and principles of operational excellence.

Ryan Nielsen

Life Sciences Global Sales Director, Rockwell Automation

Ryan Nielsen is the Life Sciences Global Sales Director at Rockwell Automation. He has over 17 years of industry experience and a passion for collaboration in solving complex problems and adding value to the life sciences space.

Shameek Ray

Head of Quality Manufacturing Informatics, Zifo

Shameek Ray is the Head of Quality Manufacturing Informatics and Zifo and has extensive experience in implementing laboratory informatics and automation for life sciences, forensics, consumer goods, chemicals, food and beverage, and crop science industries. With his background in services, consulting, and product management, he has helped numerous labs embark on their digital transformation journey.

Max Peterson​

Lab Data Automation Practice Manager, Zifo

Max Petersen is the Lab Data Automation Practice Manager at Zifo responsible for developing strategy for their Lab Data Automation Solution (LDAS) offerings. He has over 20 years of experience in informatics and simulation technologies in life sciences, chemicals, and materials applications.

Michael Stapleton

Life Sciences Luminary and Influencer

Michael Stapleton is a life sciences leader with success spanning leadership roles in software, consumables, instruments, services, consulting, and pharmaceuticals. He is a constant innovator, optimist, influencer, and digital thought leader identifying the next strategic challenge in life sciences, executing and operationalizing on high impact strategic plans to drive growth.

Matthew Schulze

Head of Digital Pioneering Medicines & Regulatory Systems, Flagship Pioneering

Matt Schulze is currently leading Digital for Pioneering Medicines which is focused on conceiving and developing a unique portfolio of life-changing treatments for patients by leveraging the innovative scientific platforms and technologies within the ecosystem of Flagship Pioneering companies.

Daniel R. Matlis

Founder and President, Axendia

Daniel R. Matlis is the Founder and President of Axendia, an analyst firm providing trusted advice to life science executives on business, technology, and regulatory issues. He has three decades of industry experience spanning all life science and is an active contributor to FDA’s Case for Quality Initiative. Dan is also a member of the FDA’s advisory council on modeling, simulation, and in-silico clinical trials and co-chaired the Product Quality Outcomes Analytics initiative with agency officials.

Kir Henrici

CEO, The Henrici Group

Kir is a life science consultant working domestically and internationally for over 12 years in support of quality and compliance for pharma and biotech. Her deep belief in adopting digital technology and data analytics as the foundation for business excellence and life science innovation has made her a key member of PDA and ISPE – she currently serves on the PDA Regulatory Affairs/Quality Advisory Board

Oliver Hesse

VP & Head of Biotech Data Science & Digitalization, Bayer Pharmaceuticals

Oliver Hesse is the current VP & Head of Biotech Data Science & Digitalization for Bayer, based in Berkeley, California. He has a degree in Biotechnology from TU Berlin and started his career in a Biotech start-up in Germany before joining Bayer in 2008 to work on automation, digitalization, and the application of data science in the biopharmaceutical industry.

John Maguire

Director of Manufacturing Sciences, Sanofi mRNA Center of Excellence

With over 18 years of process engineering experience, John is an expert in the application of process engineering and operational technology in support of the production of life science therapeutics. His work includes plant capability analysis, functional specification development, and the start-up of drug substance manufacturing facilities in Ireland and the United States.

Chris Kopinski

Business Development Executive, Life Sciences and Healthcare at AWS

As a Business Development Executive at Amazon Web Services, Chris leads teams focused on tackling customer problems through digital transformation. This experience includes leading business process intelligence and data science programs within the global technology organizations and improving outcomes through data-driven development practices.

Tim Adkins

Digital Life Science Operations, ZÆTHER

Tim Adkins is a Director of Digital Life Sciences Operations at ZÆTHER, serving the life science industry by assisting companies reach their desired business outcomes through digital IT/OT solutions. He has 30 years of industry experience as an IT/OT leader in global operational improvements and support, manufacturing system design, and implementation programs.

Blake Hotz

Manufacturing Sciences Data Manager, Sanofi

At Sanofi’s mRNA Center of Excellence, Blake Hotz focuses on developing data ingestion and cleaning workflows using digital tools. He has over 5 years of experience in biotech and holds degrees in Chemical Engineering (B.S.) and Biomedical Engineering (M.S.) from Tufts University.

Anthony DeBiase

Offering Manager, Rockwell Automation

Anthony has over 14 years of experience in the life science industry focusing on process development, operational technology (OT) implementation, technology transfer, CMC and cGMP manufacturing in biologics, cell therapies, and regenerative medicine.

Andy Zheng

Data Solution Architect, ZÆTHER

Andy Zheng is a Data Solution Architect at ZÆTHER who strives to grow and develop cutting-edge solutions in industrial automation and life science. His years of experience within the software automation field focused on bringing innovative solutions to customers which improve process efficiency.

Sue Plant

Phorum Director, Regulatory CMC, Biophorum

Sue Plant is the Phorum Director of Regulatory CMC at BioPhorum, a leading network of biopharmaceutical organizations that aims to connect, collaborate, and accelerate innovation. With over 20 years of experience in life sciences, regulatory, and technology, she focuses on improving access to medicines through innovation in the regulatory ecosystem.

Yash Sabharwal​

President & CEO, QbDVision

Yash Sabharwal is an accomplished inventor, entrepreneur, and executive specializing in the funding and growth of early-stage technology companies focused on life science applications. He has started 3 companies and successfully exited his last two, bringing a wealth of strategic and tactical experience to the team.

Joschka Buyel

Senior MSAT Scientist at Viralgen, Process and Knowledge Management Scientist at Bayer AG

Joschka is responsible for the rollout and integration of QbDVision at Bayer Pharmaceuticals. He previously worked on various late-stage projects as a Quality-by-Design Expert for Product & Process Characterization, Process Validation, and Transfers. Joschka has a Ph.D. in Drug Sciences from Bonn University and a M.S. and B.S. in Molecular and Applied Biotechnology from the RWTH University.

Luke Guerrero

COO, QbDVision

A veteran technologist and company leader with a global CV, Luke currently oversees the core business operations across QbDVision and its teams. Before joining QbDVision, he developed, grew, and led key practices for international agency Brand Networks, and spent six years deploying technology and business strategies for PricewaterhouseCoopers’ CIO Advisory consulting unit.

Gloria Gadea Lopez

Head of Global Consultancy, Business Platforms | Ph.D., Biosystems Engineering

Gloria Gadea-Lopez is the Head of Global Consultancy at Business Platforms. Using her prior extensive experience in the biopharmaceutical industry, she supports companies in developing strategies and delivering digital systems for successful operations. She holds degrees in Chemical Engineering, Food Science (M.S.), and Biosystems Engineering (Ph.D.)

Speaker Name

Speaker’s Pretty Long Title, Specialty, and Business

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam dignissim velit et est ultricies, a commodo mauris interdum. Etiam sed ante mi. Aliquam vestibulum faucibus nisi vel lacinia. Nam suscipit felis sed erat varius mollis. Mauris diam diam, viverra nec dolor et, sodales volutpat nulla. Nam in euismod orci.